

23 **Research in context**

24 Evidence before this study

25 To map this field, bibliographic searches were conducted in the *Web of Science*, which included
26 the following results: (i) COVID-19 (95,133 hits), (ii) SARS COV-2 (33,680 hits), (iii) testing
27 policy and COVID-19 (939 hits), (iv) testing policy and SARS COV-2 (340 hits), (v) testing
28 policy and COVID-19 and asymptomatic (80 hits), (vi) testing policy and SARS COV-2 and
29 asymptomatic (54 hits); (vii) test positivity and COVID-19 and validation (7 hits), and (viii) test
30 positivity and SARS CoV-2 and validation (5 hits). Therefore, before this study, testing policy in
31 relation to asymptomatic cases as well as test positivity represented a very low proportion
32 (between ~1 thousandth to ~ 1 ten thousandth) of all publications. While many articles
33 distinguished between diagnostic and screening tests, no paper was found in which testing policy
34 is mentioned as part of a process ultimately designed to isolate all infected individuals. The few
35 articles that mentioned test positivity only investigated symptomatic cases. These
36 quanti/qualitative assessments led the authors to infer that neither testing policy nor test
37 positivity had been adequately validated and/or investigated.

38

39 Added value of this study

40 We provide the first validation of test positivity as an estimate of disease prevalence under
41 rapidly changing conditions: in pandemics, disease prevalence may vary markedly within short
42 periods of time. We also address a double limitation of control campaigns against COVID-19,
43 namely: it is unknown *who* and *where* to test. Asymptomatic cases are not likely to seek medical
44 assistance: while they feel well, they silently spread this pandemic. Because they represent
45 approximately half of all infected individuals, they are a large, moving, and invisible target.

46 *Where* to find them is also unknown because (i) randomized testing is likely to fail and (ii)
47 testing is very limited. Usually, the locations where infected people reside are not randomly
48 distributed but geographically clustered, and, up to now less than four persons per thousand
49 inhabitants are tested on a given day. However, by combining geo-referenced test positivity data
50 with cost-benefit considerations, we generate approaches not only likely to induce high benefits
51 without increasing costs but also free of assumptions: we measure bio-geography as it is.

52

53 Implications of all the available evidence

54 The fact that asymptomatic cases were not tested in many countries may explain the exponential
55 growth and much higher number of deaths observed in those countries. Ineffective testing (and,
56 therefore, ineffective isolation) can also result from the absence of geo-referenced data analysis.
57 Because the geographical location where people reside, work, study, or shop is not a random
58 event, the analysis of small geographical areas is essential. Only when actual geographical
59 relationships are observed, optimal (cost-benefit oriented) testing policies can be devised.

60

61 **Summary**

62 **Background** To stop pandemics, such as COVID-19, infected individuals should be detected,
63 treated if needed, and –to prevent contacts with susceptible individuals– isolated. Because most
64 infected individuals may be asymptomatic, when testing misses such cases, epidemics may
65 growth exponentially, inducing a high number of deaths. In contrast, a relatively low number of
66 COVID-19 related deaths may occur when both symptomatic and asymptomatic cases are tested.

67 **Methods** To evaluate these hypotheses, a method composed of three elements was evaluated,
68 which included: (i) county- and country-level geo-referenced data, (ii) cost-benefit related
69 considerations, and (iii) temporal data on mortality or test positivity (TP). TP is the percentage of
70 infections found among tested individuals. Temporal TP data were compared to the tests/case
71 ratio (T/C ratio) as well as the number of tests performed/million inhabitants (tests/mi) and
72 COVID-19 related deaths/million inhabitants (deaths/mi).

73 **Findings** Two temporal TP profiles were distinguished, which, early, displayed low (~ 1 %)
74 and/or decreasing TP percentages or the opposite pattern, respectively. Countries that exhibited
75 >10 TP % expressed at least ten times more COVID-19 related deaths/mi than low TP countries.
76 An intermediate pattern was identified when the T/C ratio was explored. Geo-referenced, TP-
77 based analysis discovered municipalities where selective testing would be more cost-effective
78 than alternatives.

79 **Interpretations** When TP is low and/or the T/C ratio is high, testing detects asymptomatic
80 cases and the number of COVID-19 related deaths/mi is low. Geo-referenced TP data can
81 support cost-effective, site-specific policies. TP promotes the prompt cessation of epidemics and
82 fosters science-based testing policies.

83 **Funding** None

84 **Introduction**

85 Albert Bartlett partially dedicated his life to teaching the expressions and consequences
86 of the exponential function [1]. Epidemics –including the COVID-19 pandemic– tend to grow or
87 decline exponentially. Given the catastrophic consequences of the epidemic exponential growth
88 [2 Rudan], the first priority in epidemic control is to avoid contacts: when it takes just 60 days to
89 increase from 1 to > 60,000 COVID-19 related deaths (as observed in this pandemic),
90 ‘coexistence with the virus’ or ‘flattening the epidemic curve’ is not a likely outcome.

91 Because blocking contacts between infected and susceptible individuals prevents the
92 exponential growth of an epidemic, testing is the first priority of a control policy: it allows to
93 detect, treat if needed, and isolate all infected individuals. Hence, the WHO summarizes its
94 recommendations with three words: *test, treat, isolate* [3].

95 However, a substantial proportion of individuals infected with SARS CoV-2 may be
96 infectious even without symptoms. Hence, identifying asymptomatic cases is a crucial element in
97 epidemic control: if they were rapidly identified and subsequently isolated, the virus could be
98 removed from the environment and the pandemic would stop [4-7]. The theoretical solution for
99 this problem is to test every inhabitant of every country.

100 Unfortunately, massive testing (the type required to identify all infected individuals) is
101 not currently feasible in most countries. This situation creates a new challenge: how can major
102 disseminators of the COVID-19 pandemic be identified when testing is limited (or very limited)?

103 Therefore, a fourth action should be added to the three proposed by WHO: *identification*.
104 The determination of the geographical sites where asymptomatic cases are likely to be located is
105 the linchpin of epidemic control. However, only a minor proportion of the population is tested on
106 a given day (usually less than four per thousand inhabitants [8]). Given the scarce resources

107 available, the limited testing, and the need to remove viral spreaders before the epidemic
108 exponential growth overwhelms the anti-epidemic responses, identification should be precise,
109 rapidly implemented, and cost-effective [9-11]. To address this composite problem, new metrics
110 and methods may be required.

111 Test positivity (TP) is a concept to be considered. TP is the percentage of infections
112 detected among tested individuals. While TP has been used for more than seven decades, in the
113 context of COVID-19 it was first mentioned on March 30, 2020, by WHO [12]. Classically, TP
114 has been utilized in reference to the ability of a test to identify and distinguish infection-positive
115 from infection-negative individuals (also known as sensitivity and specificity, when the inference
116 refers to the past; or test positive/negative predictive value, when the inference refers to the
117 future). Such tests have a *diagnostic* purpose. They differ from *screening* tests [7, 13].

118 In this report, TP is viewed as a metric that may evaluate the efficacy of *testing programs*
119 aimed at detecting asymptomatic COVID-19 cases; i.e., test positivity percentages may indirectly
120 help to elucidate whether testing is or is not capturing asymptomatic cases, even when the
121 number of tests performed per million inhabitants is low. In this context, TP is a component of
122 an *epidemiologic* strategy used in a rapidly changing environment with the purpose of detecting
123 and isolating infected individuals before the epidemic exponential process consolidates.

124 To the best of our knowledge, the validity of the TP metric to detect asymptomatic cases
125 when testing is limited has not yet been demonstrated. To understand why TP percentages may
126 achieve that goal, the history of epidemics is worth revisiting. When disease prevalence is zero
127 (before an epidemic starts), the TP % is zero, too. The TP % is expected to be non-zero (but
128 relatively low) after epidemic onset. That is so because even the worst epidemics on record have
129 infected only a minor percentage of the population –for instance, the highest estimates on

130 fatalities induced by the 1918 flu pandemic are about 5% [14].

131 Accordingly, when the TP % approaches or exceeds 50% (as reported in several countries
132 affected by COVID-19), it is unlikely that such numbers reflect the actual disease prevalence.
133 Instead, high TP percentages may express testing conducted within a subpopulation that does not
134 (or only marginally) promote(s) epidemic spread: the group of *symptomatic* cases. Because
135 symptomatic cases are easily detected, they are also easily treated and isolated. Consequently,
136 symptomatic cases are not likely to disseminate epidemics. In contrast, infected but undetected
137 individuals –asymptomatic cases– transmit the disease [15].

138 Therefore, *high TP* percentages may be observed when the testing policy predominantly
139 detects *symptomatic* cases (as explicitly pursued by official policies or promoted by research
140 institutions of some countries [16-18]). This hypothesis is further supported when the alternative
141 is associated with promising outcomes, that is, when lower TP values are found in countries
142 where the testing policy explicitly captures asymptomatic cases and, later, much fewer deaths per
143 million inhabitants are reported than in countries reporting high TP percentages. This means that
144 low TP percentages may reflect the prompt removal of SARS CoV-2-positive individuals –a
145 likely outcome of policies that test asymptomatic cases. Thus, empirically elucidating whether
146 high TP percentages are found when asymptomatic cases are excluded in the testing policy as
147 well as the alternative hypothesis –low TP percentages are associated with testing programs
148 that detect asymptomatic cases– are pre-requisites of scientifically sound testing policies meant
149 to identify and isolate the spreaders of epidemics.

150 Other metrics of potential interest include: (i) the number of new cases, (ii) the number
151 of COVID-19 related deaths/million inhabitants (deaths/mi), and (iii) the ratio between the
152 number of tests and the number of cases detected (the T/C ratio). The time when the highest

153 number of new cases occur is a relevant input of epidemiologic decision-making [19]. Because
154 testing policies that only emphasize symptomatic cases will generate biased estimates on when
155 new cases peak, approaches that detect asymptomatic cases are needed [16].

156 To demonstrate that novel testing methods can capture asymptomatic cases even when
157 testing is limited, high-resolution, geo-referenced data may be required. When small
158 geographical areas report high TP percentages, intensive testing in such areas could induce
159 benefits that will include the larger surrounding area, generating high benefit-cost ratios [20].

160 Accordingly, relationships between the TP percentage, its inverse (the number of tests
161 conducted per each detected case ratio or T/C ratio), and other metrics (the number of new cases
162 and the number of deaths per million inhabitants) were investigated across countries and –using
163 geo-referenced data of high resolution – across municipalities. This study aimed at elucidating
164 whether, when and where the TP percentage and/or the T/C ratio informed earlier and/or
165 provided more information than classic metrics in reference to asymptomatic cases and, if so
166 demonstrated, whether such metrics, once geo-referenced, could foster region-specific, cost-
167 benefit oriented control policies.

168

169 **Materials and methods**

170 Methods

171 Data on new (daily) tests performed, cases identified, test positivity (the percentage of positive
172 cases/tests performed) and its inverse (the test/case ratio), as well as the cumulative number of
173 tests or deaths per million inhabitants were collected from publicly available data sources and
174 compared across countries and across time. Countries were classified as either displaying high or
175 low test positivity (TP) when, at least three months after the initiation of the epidemic, they

176 showed non-overlapping intervals of TP and such classes also revealed non-overlapping intervals
177 of epidemic-related outcomes (deaths/million inhabitants). Differences in median deaths/million
178 inhabitants between low TP and high TP countries were investigated with the Mann-Whitney test
179 using a commercial statistical package (Minitab LLC, State College, PA, USA). Geographical
180 data were processed with ARC GIS software (ESRI, Redlands, Ca, USA). Thirteen countries
181 were evaluated because, together, they exhibited geographical and demographic diversity and
182 individually, they were affected by COVID-19 long enough (two or more months) so they could
183 reveal exponential epidemic growth, if it happened. Such countries were: Bangladesh, Belgium,
184 Colombia, Cyprus, Ethiopia, Germany, Greece, Italy, South Africa, South Korea, Spain,
185 Uruguay, and the United States. To explore georeferenced data on test positivity, the
186 municipality-specific data reported by Harvard University on Puerto Rico were analyzed
187 [<https://rconnect.dfc.harvard.edu/covidpr/?s=08>]. Because many countries have reported errors
188 and/or changed the definition of cases and deaths and because not all affected countries were
189 investigated, inferences should not be construed to be representative. However, inferences
190 derived from patterns observed in two or more countries (or regions of a country) may be viewed
191 as plausible and, possibly, generalizable.

192

193 Data

194 Data were extracted from *Worldometer* and/or governmental sites (
195 <https://www.worldometers.info/coronavirus/>; <https://www.pio.gov.cy/coronavirus/eng> ;
196 <https://eody.gov.gr/epidimiologika-statistika-dedomena/ektheseis-covid-19/> ;
197 <https://www.gub.uy/sistema-nacional-emergencias/>).

198

199 **Results**

200 Test positivity-related temporal patterns

201 Findings revealed two temporal patterns: (i) one characterized by an early TP peak (the
202 highest TP percentages took place in the first weeks), followed by a rapid decline to ~ 1% (four
203 countries, green rectangles, Figs. 1 A-D); and (ii) a pattern shared by six countries, which
204 showed later and increasing TP values, even >10%, over one or more weeks (red rectangles,
205 Figs. 1 E-J). In addition, the data of ten countries consistently demonstrated that the highest TP
206 percentages occurred earlier or at the same time as, but not later than the number of new cases
207 (Fig. 1 A-J). The first pattern (low TP percentage) was associated with a quasi-complete
208 cessation of the epidemic within four months. The second pattern (high TP percentages) was
209 shown by countries where, four to six months into the epidemic, the median number of deaths/mi
210 was at least 10 times higher than in countries displaying the alternative pattern ($p < 0.02$, Fig. 2).

211

212 Validation of TP-based testing policies designed to detect asymptomatic cases

213 Four-dimensional (3D and temporal) plots that included TP percentages and T/C ratios
214 identified three profiles, characterized by: (i) high TP percentages (data points shown only in the
215 upper right quadrant, 4 countries); (ii) a hybrid pattern, which exhibited high TP and some high
216 T/C observations (one country); and (iii) countries predominantly displaying high T/C ratio
217 values (four countries, Figs. 3 A-I). TP values less than 5 % did not predict the end of the
218 epidemic –even countries displaying < 1% TP over more than two weeks failed to report zero
219 cases after such a period of time (Figs. 4 A-D).

220

221 Exploration of geo-referenced and temporal TP as tools of cost-effective policies

222 To investigate the hypothesis that geo-referenced and temporal TP data support site-
223 specific, cost-effective interventions, the test positivity percentages reported in all municipalities
224 of Puerto Rico on September 11, 2020, were investigated. One municipality reported a TP
225 >50%, which was surrounded by 17 municipalities that reported much lower TPs. Assuming that
226 testing resources (including tests) were distributed according to the size of the population, the
227 municipality with >50% TP received 1/42 of such resources and the remaining municipalities
228 obtained testing-related resources 42 times larger in magnitude (Fig. 5).

229 Such a situation facilitated cost-benefit oriented, geographically and epidemiologically
230 specific interventions. For instance, if the level of testing implemented in area 1 (the
231 municipality with >50% TP) was decided to be increased 1000%, immediately –but no new
232 resources were provided–, the additional tests required in area 1 could only come from area 2.
233 This means that 10 of the original 43 units of resources spent in areas 1 and 2 (1 unit spent in
234 area 1 and 42 units spent in area 2) would now be used in area 1 (a 1000% increase). This
235 solution would cause a 23.56 % reduction (from 42 to 32) in the units of resources spent in area 2
236 – a region barely affected by the epidemic and, therefore, highly vulnerable (Fig. 5).

237 These data also estimated the costs of random testing and/or testing that ignores geo-
238 temporal cost-benefit considerations. If the surrounding area (area 2) was affected as much as
239 area 1, the size of epidemic could increase 42 times (Fig. 5). This epidemic growth could occur
240 even if testing continued, uninterruptedly, at the same level as previously performed.

241

242 Additional tools

243 Relationships between metrics elucidated when testing was or was not adequate.

244 Examples collected from 14 countries revealed when testing grew faster than cases (a desirable

245 outcome) or the alternative pattern suggested additional testing was needed (Fig. 6A-D). The use
246 of the number of deaths per million inhabitants was also informative (Figs. 6 E-H).

247

248 **Discussion**

249 Because asymptomatic patients rarely request medical assistance, they may become the
250 invisible spreaders of epidemics. Consequently, testing, treating, and isolating such cases should
251 be prioritized [3]. However, given that testing is usually limited, their identification is
252 problematic [8]. This compounded problem was addressed with an approach that, considering
253 test positivity (TP), evaluated testing policies that prioritize the detection of asymptomatic cases
254 and also considers geo-referenced, cost-benefit oriented data analysis.

255 Testing symptomatic or asymptomatic cases may depend on medical and public health-
256 related perspectives [7]. For instance, testing that emphasizes symptomatic cases differs from
257 screening-oriented testing. In the first case, it is assumed that epidemics can be stopped through
258 interventions conducted within hospitals –as when individuals that feel ill seek medical
259 assistance. It is expected to find high percentages of test positivity when *confirmatory* testing is
260 promoted (the type of testing physicians are likely to prescribe). While this type of testing (or
261 purpose) is necessary when a clinical perspective is considered, it does not contribute much to
262 prevent epidemic spread, which depends on early detection of asymptomatic cases [7,18]. In
263 contrast, in population medicine, *epidemiologic* testing is needed (screening or information
264 usable in epidemic control, not only in clinical medicine). Here it was hypothesized that lower
265 TP percentages predicted lower numbers of deaths per million inhabitants than when higher TP
266 percentages were observed –findings consistent with the hypothesis that asymptomatic cases are
267 detected when the percentage of TP is low. Findings supported these hypotheses, opening a path

268 toward scientifically grounded testing policies that seek to detect (and immediately isolate)
269 asymptomatic –not only symptomatic– cases [7, 18]. As expected, countries that displayed high
270 TP percentages in early epidemic stages, later reported many more deaths/mi than low TP
271 countries. These findings supported the notion that, in high TP countries, asymptomatic cases
272 were missed and, consequently, the epidemic grew exponentially and so did deaths.

273 The epidemics here investigated also showed that TP peaks occur earlier than the peak
274 number of new cases. Data turning points (which include peaks) help to conduct epidemiologic
275 forecasts [21].

276 Findings also addressed the statement made by WHO on May 12, 2020, which suggested
277 that low (<5%) TP values over two consecutive weeks signal that an epidemic is under control
278 [22]. This study found that even 1% TP was associated with longer epidemics (Figs. 3 A-D).

279 The fact that neither a 5% nor a 1 % TP cutoff predicted the immediate cessation of an
280 epidemic was expected: dichotomization of continuous data promotes errors. Such a procedure
281 assumes that the discrete (discontinuous) nature of a process can change below or above a cutoff
282 generated by continuous data. Yet, the evidence demonstrated that an ‘epidemic-positive’
283 country does not become an ‘epidemic-negative’ one when TP changes from 5.00 to 4.99 %.
284 While pattern recognition can discriminate without numerical cutoffs (as Fig. 5 shows), the
285 dichotomization assumption tends to lose information and generates errors [23].

286 Therefore, TP seems a robust and explanatory metric. Unlike the number of new cases,
287 TP may inform *when* (and, provided that geo-referenced information is also available, *where*)
288 spikes of its percentage will identify specific places that require additional testing so
289 asymptomatic cases can be rapidly detected, isolated, and treated [24]. However, to prevent such
290 patients from promoting exponential epidemic growth, early and geographically-specific

291 responses are needed. Here, an operational model showed that observable geo-epidemiologic
292 features can generate site-specific, cost-effective interventions.

293 Investigating geo-referenced epidemiologic data matters because humans are not
294 homogeneously distributed in space. Lakes, railroads, schools and many other (geographically
295 specific) entities both separate and connect humans. While some geographical points act as
296 epidemic nodes, many points do not seem to influence epidemic spread [25].

297 While earlier studies have conducted cost-benefit analysis of COVID-19 control policies,
298 they lacked geo-referenced data [26]. The geo-referenced, cost-benefit theory followed in this
299 study assumed that epidemics disseminate as floods do: from a ‘higher’ point (where disease
300 prevalence or its surrogate, test positivity, is higher) toward surrounding areas where test
301 positivity percentages are lower. When cost-benefit oriented interventions are not immediately
302 implemented in such situations, the epidemiologic condition of the surrounding region can
303 rapidly worsen. This epidemiologic ‘flood’ metaphor was empirically supported: rapid
304 interventions in small areas that threaten larger areas tend to be highly cost-effective and may
305 stop epidemics (Fig. 4).

306 While aggregate (state- or country- level) data do not reveal spatial relationships and,
307 therefore, are not very useful [27], non-aggregate geo-referenced information –e.g., data on
308 neighborhoods– are epidemiologically usable, as shown with municipality-level information
309 collected in Puerto Rico (Fig. 5). When geographical-epidemiological relationships are
310 considered, it is possible to identify policies that benefit not only the area of direct intervention
311 but also the surrounding area –as commonly practiced in flood protection-related policies [28].
312 This approach has also been described as the ‘wrong pocket problem’, i.e., the area where the
313 investment is made does not only benefit from it: a larger area is benefited as well [29]. One

314 example of this geographically grounded, cost-benefit oriented approach has recently been
315 applied in an emergency vaccination against rabies conducted in Tanzania, where a limited
316 intervention in a small ring that surrounded a large city also benefitted the large city [11].

317 Findings support the view that, to stop epidemic exponential growth, testing policies should
318 aim at detecting all infected individuals (including asymptomatic cases). In spite of its relevance,
319 testing policy seems an area that lacks interdisciplinary scientific expertise. Approaches that
320 include temporal and geo-referenced test positivity data, as well as cost-benefit oriented
321 considerations, may contribute toward filling that gap.

322

323 **Contributors**

324 All authors contributed to model design, interpretation of results, and writing of the report. ALR,
325 ALH, AI, AA and PV collected data. JBH and FOF transcribed and analyzed the data. JLF made
326 maps, ALR and MHVvR drafted the manuscript.

327

328 **Declaration of interests**

329 We declare no competing interests.

330

331 **Data sharing**

332 No primary data were collected for this study, which used publicly available data. The sources of
333 the data used are described in this article.

334

335 **Funding**

336 No funding was received from any agency in the commercial or non-profit sectors.

337

338 **References**

- 339 1. Arithmetic, Population and Energy - a talk by Al Bartlett.
340 https://www.albartlett.org/presentations/arithmetric_population_energy_video1.html
341 [\(accessed Dec 5, 2020\)](#)
- 342 2. Rudan I. A cascade of causes that led to the COVID-19 tragedy in Italy and in other
343 European Union countries. *J Glob Health* 2020; **10**: 010335.
344 <https://doi.org/10.7189/jogh.10.010335>
- 345 3. World Health Organization. WHO coronavirus briefing: Isolation, testing and tracing
346 comprise the 'backbone' of response. [https://www.weforum.org/agenda/2020/03/testing-](https://www.weforum.org/agenda/2020/03/testing-tracing-backbone-who-coronavirus-wednesdays-briefing/)
347 [tracing-backbone-who-coronavirus-wednesdays-briefing/](#) (accessed Dec 5, 2020)
- 348 4. Anderson RM, Heesterbeek H, Klinkenberg D, Hollingsworth TD. How will country-based
349 mitigation measures influence the course of the COVID-19 epidemic? *Lancet* 2020; **395**:
350 931–934. [https://doi.org/10.1016/S0140-6736\(20\)30567-5](https://doi.org/10.1016/S0140-6736(20)30567-5)
- 351 5. Gandhi M, Yokoe DS, Havlir DV. Asymptomatic transmission, the Achilles' Heel of
352 current strategies to control COVID-19. *N Engl J Med* 2020; **382**: 2158–2160.
353 <https://doi.org/10.1056/NEJMe2009758>.
- 354 6. Han MS, Choi EH, Chang SH, et al. Clinical characteristics and viral RNA detection in
355 children with coronavirus disease 2019 in the Republic of Korea. *JAMA Pediatr* 2020;
356 Published online August 21. <https://doi.org/10.1001/jamapediatrics.2020.3988>
- 357 7. Raffle AE, Pollock AM, Harding-Edgar L. Covid-19 mass testing programmes. *BMJ* 2020;
358 **370**: m3262. <http://dx.doi.org/10.1136/bmj.m3262>
- 359 8. Ourworldindata. Coronavirus (COVID-19) Testing. [https://ourworldindata.org/coronavirus-](https://ourworldindata.org/coronavirus-testing)
360 [testing](#) (accessed Oct 28, 2020)

- 361 9. Rivas AL, [Tennenbaum](#) SE, [Aparicio](#) JP, et al. Critical response time (time available to
362 implement effective measures for epidemic control): model building and evaluation. *Can J*
363 *Vet Res* 2003; **67**: 307–311.
- 364 10. Rivas AL, Fasina FO, Hoogesteyn AL, et al. Connecting network properties of rapidly
365 disseminating epizoonotics. *PLoS One* 2012; **7**: e39778.
366 <https://doi.org/10.1371/journal.pone.00397782012>
- 367 11. Fasina FO, Mtui-Malamsha N, Mahiti GR, et al. Where and when to vaccinate?
368 Interdisciplinary design and evaluation of the 2018 Tanzanian anti-rabies campaign. *IJID*
369 2020; **95**: 352–360. <https://doi.org/10.1016/j.ijid.2020.03.037>
- 370 12. World Health Organization. COVID-19-virtual press conference -30 March 2020.
371 [https://www.who.int/docs/default-source/coronaviruse/transcripts/who-audio-emergencies-](https://www.who.int/docs/default-source/coronaviruse/transcripts/who-audio-emergencies-coronavirus-press-conference-full-30mar2020.pdf?sfvrsn=6b68bc4a_2)
372 [coronavirus-press-conference-full-30mar2020.pdf?sfvrsn=6b68bc4a_2](https://www.who.int/docs/default-source/coronaviruse/transcripts/who-audio-emergencies-coronavirus-press-conference-full-30mar2020.pdf?sfvrsn=6b68bc4a_2) (accessed July 20,
373 2020).
- 374 13. Speechley M, Kunnilathu A, Aluckal E, et al. Screening in Public Health and Clinical Care:
375 similarities and differences in definitions, types, and aims – a systematic review. *J Clin Diagnostic*
376 *Res* 2017; **11**: LE01–LE04.
377 <https://doi.org/10.7860/JCDR/2017/24811.9419>
- 378 14. Roser M. The Spanish flu (1918-20): The global impact of the largest influenza pandemic in
379 history. <https://ourworldindata.org/spanish-flu-largest-influenza-pandemic-in-history>
380 (accessed Sept 24, 2020).
- 381 15. Basnarkov L. SEAIR epidemic spreading model of COVID-19. arXiv:2005.11815v2
382 [physics.soc-ph] <http://arxiv.org/abs/2005.11815v2>
- 383 16. Iosa M, Paolucci S, Morone G. Covid-19: A dynamic analysis of fatality risk in Italy. *Front.*

- 384 *Med.* 2020, **7**: 185. <https://doi.org/10.3389/fmed.2020.00185>
- 385 17. Deutsche Welle. Germany's coronavirus response: Separating fact from fiction.
- 386 [https://www.dw.com/en/germanys-coronavirus-response-separating-fact-from-fiction/a-](https://www.dw.com/en/germanys-coronavirus-response-separating-fact-from-fiction/a-53053822)
- 387 [53053822](https://www.dw.com/en/germanys-coronavirus-response-separating-fact-from-fiction/a-53053822) (accessed Dec 5, 2020).
- 388 18. Padula WV. Why only test symptomatic patients? Consider random screening for
- 389 COVID-19. *Appl Health Econ Health Policy* 2020; **18**: 333–334.
- 390 <https://doi.org/10.1007/s40258-020-00579-4>
- 391 19. Tsallis C, Tirnakli U. Predicting COVID-19 peaks around the world. *Front Phys* 2020;
- 392 **8**: 217. <https://doi.org/10.3389/fphy.2020.00217>
- 393 20. Rivas AL, Hoogesteijn AL, Hittner JB, et al. Addressing a complicated problem: can
- 394 COVID-19 asymptomatic cases be detected – and epidemics stopped– when testing is limited
- 395 and the location of such cases unknown? medRxiv preprint
- 396 <https://doi.org/10.1101/2020.11.10.20223495>
- 397 21. Liu Z, Magal P, Webb G. Predicting the number of reported and unreported cases for the
- 398 COVID-19 epidemics in China, South Korea, Italy, France, Germany and United Kingdom.
- 399 medRxiv preprint doi: <https://doi.org/10.1101/2020.04.09.20058974>
- 400 22. World Health Organization. Considerations for implementing and adjusting public health and
- 401 social measures in the context of COVID-19. [https://www.who.int/publications/i/item/public-](https://www.who.int/publications/i/item/public-health-criteria-to-adjust-public-health-and-social-measures-in-the-context-of-covid-19)
- 402 [health-criteria-to-adjust-public-health-and-social-measures-in-the-context-of-covid-19](https://www.who.int/publications/i/item/public-health-criteria-to-adjust-public-health-and-social-measures-in-the-context-of-covid-19)
- 403 (accessed: Sept 4, 2020).
- 404 23. Altman DG, Royston P. The cost of dichotomising continuous variables. *BMJ* 2006; **332**:
- 405 1080. <https://doi.org/10.1136/bmj.332.7549.1080>
- 406 24. Machanick P. Revisiting early-stage COVID-19 strategy options [version 2; peer review:

- 407 awaiting peer review] *F1000 Research* 2020, 9:327.
- 408 <https://doi.org/10.12688/f1000research.23524.2>
- 409 25. Rivas AL, Febles JL, Smith SD, et al. 2020 Early network properties of the COVID-19
410 pandemic – the Chinese scenario. *IJID* 2020; **96**: 519–523.
- 411 26. Reddy KP, Shebl KM, Foote JHA, et al. Cost-effectiveness of public health strategies for
412 COVID-19 epidemic control in South Africa. *Lancet Glob Health* 2020; Nov 11:S2214-
413 109X(20)30452-6. [https://doi.org/10.1016/S2214-109X\(20\)30452-6](https://doi.org/10.1016/S2214-109X(20)30452-6)
- 414 27. Ortiz-Pelaez A, Pfeiffer DU, Soares-Magalhães RJ, Guitian FJ. Use of social network
415 analysis to characterize the pattern of animal movements in the initial phases of the 2001 foot
416 and mouth disease (FMD) epidemic in the UK. *Prev Vet Med* 2006; **76**: 40–55.
417 <https://doi.org/10.1016/j.prevetmed.2006.04.007>
- 418 28. Syrbe R-U, Walz U. Spatial indicators for the assessment of ecosystem services: Providing,
419 benefiting and connecting areas and landscape metrics. *Ecol Indic* 2012; **21**: 80–88.
420 <https://doi.org/10.1016/j.ecolind.2012.02.013>
- 421 29. McCullough JM. Declines in spending despite positive returns on investment: understanding
422 Public Health’s Wrong Pocket Problem. *Front Public Health* 2019; **7**: 159.
423 <https://doi.org/10.3389/fpubh.2019.00159>
- 424

425 **Figure legends**

426 **Fig. 1. Temporal relationships between the test positivity percentage and the number of**

427 **new cases.** Two epidemic patterns were differentiated among 10 countries: (i) epidemics that
428 revealed a rapid decrease in the test positivity (TP) percentage and, subsequently, displayed very
429 low (<1%) TP values (green rectangles, **A-D**); and (ii) epidemics that reported either later TP
430 peaks, increasing percentages of the TP over two or more weeks, and/or TP percentages higher
431 than 5% (red rectangles, **E-J**). In all ten countries investigated, the peak TP percentage occurred
432 earlier than the peak number of new cases. Source: *Worldometer*.

433

434 **Fig. 2. Temporal relationships between test positivity percentage and deaths per million**

435 **inhabitants.** By August 25, 2020 (at least four months into the epidemic), the group of countries
436 that, earlier, reported high (three-digit) test positivity percentages (high TP) showed at least 10
437 times more deaths per million inhabitants (d/mi) than countries that, earlier displayed low (two-
438 digit) TP percentages ($p < 0.02$, Mann-Whitney test). High and low TP countries revealed non-
439 overlapping data intervals (rectangles). Source: *Worldometer*.

440

441 **Fig. 3. Temporal relationships between test positivity and the tests/case ratio.** The

442 assessment of the tests/case ratio revealed more information when nine countries were
443 investigated, which partially included the set reported in Fig. 1. Four countries showed high TP
444 percentages but few or no high tests/case ratios (**A-D**). One country displayed a hybrid pattern,
445 which was characterized by a few high TP percentages and a few high tests/case ratios (**E**). The
446 remaining four countries predominantly exhibited high tests/case ratios (**F-I**).

447

448 **Fig. 4. Pattern- vs. threshold-based evaluations of epidemic control measures.** Four

449 countries located in three continents showed new cases even when the percentage of test
450 positivity (TP) was $< 1\%$ (ovals, **A-D**). Because new cases were observed over protracted (more
451 than two-week long) periods of time, it is concluded that no numerical cutoff (e.g., $TP < 5\%$)
452 indicates an epidemic is under control. In contrast, patterns –such as a perpendicular data
453 inflection– promote inferences, regardless of any cutoff value.

454


455 **Fig. 5. Geo-epidemiologically specific, cost-benefit effective, differential testing.** The test
456 positivity (TP) percentages reported in all municipalities of Puerto Rico, on Sept 11, 2020, are
457 depicted. Area 1 shows the municipality of Jayuya. Area 2 identifies a larger, surrounding region
458 that includes ~42 times more people and covers an area ~ 8.5 times larger than those of Jayuya.
459 Given Jayuya +50% TP, a greater testing effort conducted in this municipality may yield large
460 benefits, which may also include the surrounding area (Area 2) and, indirectly, benefit the
461 western half of the island. Vice versa, keeping the same level of testing performed before may
462 lead to long-lasting, costly consequences: if the virus circulating within Jayuya reached the
463 surrounding area and the prevalence of COVID-19 became similar to the one affecting Jayuya
464 (which is estimated by test positivity), then a much larger number of people (up to 42 times
465 larger) could become infected, who would reside in an area 8.5 times larger, i.e., control would
466 then be much harder, longer and costlier.

467


468 **Fig. 6. Relationships between outcomes (non-fatal or fatal infections) and the number of**
469 **tests/million inhabitants.** Testing policies may be adjusted based on patterns generated by
470 cases (**A-D**) and fatalities (**E-H**). When testing grows slower than cases or deaths (when the
471 curvature approaches a vertical pattern), testing is likely to be insufficient or inadequate.

472

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).




474 **Fig. 1. Temporal relationships between the test positivity percentage and the number of**
475 **new cases.** Two epidemic patterns were differentiated among 10 countries: (i) epidemics that
476 revealed a rapid decrease in the test positivity (TP) percentage and, subsequently, displayed very
477 low (<1%) TP values (green rectangles, **A-D**); and (ii) epidemics that reported either later TP
478 peaks, increasing percentages of the TP over two or more weeks, and/or TP percentages higher
479 than 5% (red rectangles, **E-J**). In all ten countries investigated, the peak TP percentage occurred
480 earlier than the peak number of new cases. Source: *Worldometer*.
481
482




483
484 **Fig. 2. Temporal relationships between test positivity percentage and deaths per million**
485 **inhabitants.** By August 25, 2020 (at least four months into the epidemic), the group of countries
486 that, earlier, reported high (three-digit) test positivity percentages (high TP) showed at least 10
487 times more deaths per million inhabitants (d/mi) than countries that, earlier displayed low (two-
488 digit) TP percentages ($p < 0.02$, Mann-Whitney test). High and low TP countries revealed non-
489 overlapping data intervals (rectangles). Source: *Worldometer*.

490
491




492
493
494
495
496
497
498
499
500

Fig. 3. Temporal relationships between test positivity and the tests/case ratio. The assessment of the tests/case ratio revealed more information when nine countries were investigated, which partially included the set reported in Fig. 1. Four countries showed high TP percentages but few or no high tests/case ratios (A-D). One country displayed a hybrid pattern, which was characterized by a few high TP percentages and a few high tests/case ratios (E). The remaining four countries predominantly exhibited high tests/case ratios (F-I).




501
502 **Fig. 4. Pattern- vs. threshold-based evaluations of epidemic control measures.** Four
503 countries located in three continents showed new cases even when the percentage of test
504 positivity (TP) was $< 1\%$ (ovals, **A-D**). Because new cases were observed over protracted (more
505 than two-week long) periods of time, it is concluded that no numerical cutoff (e.g., $TP < 5\%$)
506 indicates an epidemic is under control. In contrast, patterns –such as a perpendicular data
507 inflection– promote inferences, regardless of any cutoff value.
508



509
510











511 **Fig. 5. Geo-epidemiologically specific, cost-benefit effective, differential testing.** The test
512 positivity (TP) percentages reported in all municipalities of Puerto Rico, on Sept 11, 2020, are
513 depicted. Area 1 shows the municipality of Jayuya. Area 2 identifies a larger, surrounding region
514 that includes ~42 times more people and covers an area ~ 8.5 times larger than those of Jayuya.
515 Given Jayuya +50% TP, a greater testing effort conducted in this municipality may yield large
516 benefits, which may also include the surrounding area (Area 2) and, indirectly, benefit the
517 western half of the island. Vice versa, keeping the same level of testing performed before may
518 lead to long-lasting, costly consequences: if the virus circulating within Jayuya reached the
519 surrounding area and the prevalence of COVID-19 became similar to the one affecting Jayuya
520 (which is estimated by test positivity), then a much larger number of people (up to 42 times
521 larger) could become infected, who would reside in an area 8.5 times larger, i.e., control would
522 then be much harder, longer and costlier.

523













524





525 **Fig. 6. Relationships between outcomes (non-fatal or fatal infections) and the number of**
526 **tests/million inhabitants.** Testing policies may be adjusted based on patterns generated by
527 cases (A-D) and fatalities (E-H). When testing grows slower than cases or deaths (when the
528 curvature approaches a vertical pattern), testing is likely to be insufficient or inadequate.



Deaths/million inhabitants (August 25, 2020)





A**CYPRUS****B****GREECE****D****S. KOREA****D****URUGUAY**


67°W


66°W


18°N

17°N

TP_Sep11



 Area 1 = 117.4 km²
Population 1 = 13,891

 Area 2 = 2,467.1 km²
Population 2 = 589,463

